SCHEMBL6087945

SCHEMBL6087945

O=C1CCC(c2c[nH]c3cccc(Br)c23)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.54
CYP2A6 P11509 1/20 0.43
IKBKB O14920 2/20 0.39
PARP1 P09874 1/20 0.34
DRD2 P14416 1/20 0.34
DRD1 P21728 1/20 0.34
DRD5 P21918 1/20 0.34
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR3 P22607 1/20 0.34
IDO1 P14902 3/20 0.33
ADRB2 P07550 1/20 0.33
HTR2C P28335 1/20 0.33
CLK1 P49759 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
HTR1A P08908 1/20 0.33
LMNA P02545 1/20 0.33
HTR1F P30939 1/20 0.33
FEN1 P39748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087284 0.83 SLC6A4 (0.54) SLC6A4IKBKBPARP1DRD2DRD1
SCHEMBL6087789 0.79 SLC6A4 (0.55) SLC6A4IKBKBPARP1ADRB2HTR2C
SCHEMBL1413420 0.77 HTR2C (0.58) IKBKBIDO1ADRB2HTR2CLMNA
SCHEMBL6638279 0.74 SLC6A4 (0.56) SLC6A4IKBKBADRB2HTR2CHTR1A
SCHEMBL3234820 0.74 SLC6A4 (0.47) SLC6A4CYP2A6PARP1DRD2DRD1
SCHEMBL6087540 0.72 IDO1 (0.56) SLC6A4IKBKBIDO1HTR1A
SCHEMBL6087543 0.72 IDO1 (0.56) SLC6A4CYP2A6IKBKBIDO1
SCHEMBL6086622 0.70 SLC6A4 (1.00) SLC6A4DRD1HTR1A
SCHEMBL23409377 0.69 MAPT (0.38) IKBKB
SCHEMBL14168901 0.69 HTR2C (0.55) IKBKBIDO1ADRB2HTR2CHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7049314-B2 Sexual disorders; antidepressants; attention deficit hyperactivity, obsessive-compulsive, and/or post-traumatic stress disorder; drug abuse and addiction BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-23 US disclosed
US-20040077705-A1 Cyclopentyl indole derivatives BRISTOL-MYERS SQUIBB COMPANY 2004-04-22 US disclosed
WO-2004026236-A2 CYCLOPENTYL INDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077705-A1 Cyclopentyl indole derivatives HTR5A, TPH1, TPH2 SLC6A4 11/4885CYP2A6 259/4885IKBKB 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.